

# Qiong Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7505313/publications.pdf>

Version: 2024-02-01

8  
papers

263  
citations

1478505

6  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

458  
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2 positive bilateral metachronous primary breast carcinoma: A case report. <i>Cancer Biology and Therapy</i> , 2018, 19, 349-354.	3.4	2
2	First-line treatment of apatinib in elderly patient of advanced gastric carcinoma: A case report of NGS-driven targeted therapy. <i>Cancer Biology and Therapy</i> , 2018, 19, 355-358.	3.4	2
3	PHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 65.	8.6	20
4	MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 19.	8.6	71
5	The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. <i>Oncotarget</i> , 2015, 6, 7000-7010.	1.8	55
6	Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition. <i>Oncology Reports</i> , 2014, 31, 540-550.	2.6	43
7	Arsenic Trioxide Targets miR-125b in Glioma Cells. <i>Current Pharmaceutical Design</i> , 2014, 20, 5354-5361.	1.9	14
8	Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. <i>Oncotarget</i> , 2013, 4, 1999-2009.	1.8	56